Nektar Therapeutics to Report Phase 2b Atopic Dermatitis Trial Results for Novel Regulatory T-Cell Therapy
核心洞察
Nektar Therapeutics will announce top-line data from the 16-week induction period of its global Phase 2b REZOLVE-AD trial on June 24, 2025.
The trial evaluates rezpegaldesleukin, a first-in-class regulatory T-cell (搜索) proliferator, for treating moderate-to-severe atopic dermatitis (搜索).
Rezpegaldesleukin represents a novel approach targeting underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
Nektar Therapeutics announced it will release top-line data from the 16-week induction period of its ongoing global Phase 2b REZOLVE-AD clinical trial on June 24, 2025. The trial is evaluating rezpegaldesleukin, an investigational regulatory T-cell (搜索) (Treg) proliferator, for the treatment of moderate-to-severe atopic dermatitis (搜索).
The San Francisco-based clinical-stage biotechnology company will host an investor call and live webcast at 8:15am ET / 5:15am PT to review the results. The data will be provided in a morning press release and presented during the webcast, with a replay available for at least 30 days following the event.
Novel Regulatory T-Cell Approach
Rezpegaldesleukin, also known as REZPEG or NKTR-358, represents a first-in-class regulatory T cell stimulator designed to address underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The drug candidate is Nektar's lead product and is currently being evaluated in two separate Phase 2b clinical trials.
Beyond the atopic dermatitis (搜索) trial, Nektar is conducting a second Phase 2b study of rezpegaldesleukin for alopecia areata (搜索), demonstrating the potential broad applicability of this regulatory T-cell (搜索) approach across multiple autoimmune conditions.
Expanding Pipeline
Nektar's development pipeline extends beyond rezpegaldesleukin to include several other investigational therapies. The company is advancing preclinical programs including a bivalent tumor necrosis factor receptor type II (TNFR2 (搜索)) antibody and bispecific programs designated NKTR-0165 and NKTR-0166, as well as NKTR-422, a modified hematopoietic colony stimulating factor (CSF) protein.
Additionally, Nektar is collaborating with various partners to evaluate NKTR-255, an investigational IL-15 receptor (搜索) agonist designed to enhance the immune system's natural ability to fight cancer, in several ongoing clinical trials.
The upcoming data release represents a significant milestone for Nektar's regulatory T-cell (搜索) platform and could provide important insights into the therapeutic potential of targeting Treg cells for treating inflammatory skin conditions.